PYXS Pyxis Oncology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PYXS

Price (delayed)

$3.565

Market cap

$297.35M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.41

Enterprise value

$294.85M

?
Relative Growth: Rel. Growth: 24
Relative Strength: Rel. Strength: 98
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 22

Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination indications. ...

Highlights
Pyxis Oncology's debt has decreased by 8% YoY and by 2.3% QoQ
PYXS's EPS is up by 11% year-on-year but it is down by 8% since the previous quarter
Pyxis Oncology's net income has decreased by 9% QoQ but it has increased by 8% YoY
The equity has plunged by 87% YoY and by 63% from the previous quarter
PYXS's quick ratio has dropped by 76% year-on-year and by 51% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.pyxisoncology.com
Peers: ONC MRNA NVAX INO

Key stats

What are the main financial stats of PYXS

PYXS stock price

How has the Pyxis Oncology stock price performed over time
Intraday
-4.93%
1 week
7.38%
1 month
17.27%
1 year
142.52%
YTD
210%
QTD
18.44%

Financial performance

How have Pyxis Oncology's revenue and profit performed over time
Revenue
$11.04M
Gross profit
$8.65M
Operating income
-$92.11M
Net income
-$88.73M
Gross margin
78.4%
Net margin
-803.8%
PYXS's operating margin has surged by 78% year-on-year but it is down by 35% since the previous quarter
Pyxis Oncology's net margin has surged by 76% YoY but it has decreased by 36% QoQ
Pyxis Oncology's gross profit has decreased by 25% QoQ
PYXS's gross margin is down by 22% year-on-year and by 5% since the previous quarter

Price vs fundamentals

How does PYXS's price correlate with its fundamentals

Growth

What is Pyxis Oncology's growth rate over time

Valuation

What is Pyxis Oncology stock price valuation
P/E
N/A
P/B
19.74
P/S
20.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.71
PYXS's EPS is up by 11% year-on-year but it is down by 8% since the previous quarter
The equity has plunged by 87% YoY and by 63% from the previous quarter
Pyxis Oncology's revenue has decreased by 20% from the previous quarter
PYXS's P/S is 11% above its last 4 quarters average of 19.6

Efficiency

How efficient is Pyxis Oncology business performance
The return on equity has dropped by 160% year-on-year and by 59% since the previous quarter
The ROIC has plunged by 90% YoY and by 47% from the previous quarter
Pyxis Oncology's ROA has plunged by 78% YoY and by 32% from the previous quarter
PYXS's return on sales has surged by 77% year-on-year but it is down by 37% since the previous quarter

Dividends

What is PYXS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PYXS.

Financial health

How did Pyxis Oncology financials performed over time
The company's total assets is 26% higher than its total liabilities
PYXS's quick ratio has dropped by 76% year-on-year and by 51% since the previous quarter
PYXS's current ratio has dropped by 76% year-on-year and by 51% since the previous quarter
Pyxis Oncology's debt is 56% higher than its equity
The debt to equity has surged by 169% since the previous quarter
The equity has plunged by 87% YoY and by 63% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.